Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| AR ARCTArcturus Therapeutics | $13.45+22.4% | $382.3M | 7 assetsPhase 2 | ARCT-810 Phase 2 · Data readout | |
| AR ARDXArdelyx Inc. | $3.89-0.3% | $1.00B | 5 assetsPhase 3 |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
| AR ARGXArgenx | $1039.78+0.2% | $52.94B | 29 assetsApproved | Empasiprubart Phase 2 · Data readout |
| AR ARMPArmata Pharmaceuticals | $5.10+15.4% | $189.6M | 3 assetsStage unavailable | No dated catalyst |
| AR ARQTArcutis Biotherapeutics | $25.08-1.1% | $3.15B | 14 assetsPDUFA | ZORYVE/Roflumilast (ARQ-154) (PDE4 Inhibitor)Phase 2 · Data readout |
| AR ARTVArtiva Biotherapeutics | $10.93-1.9% | $534.4M | 5 assetsStage unavailable | No dated catalyst |
| AR ARVNArvinas Inc. | $9.37+3.8% | $604.2M | 15 assetsApproved | ARV-393Phase 1 · Data readout |
| AR ARWRArrowhead Pharmaceuticals | $87.11-0.4% | $12.30B | 19 assetsPhase 3 | Plozasiran (ARO-APOC3) Phase 3 · Data readout |
| AS ASMBAssembly Biosciences | $34.38+2.5% | $700.0M | 8 assetsStage unavailable | No dated catalyst |
| AS ASNDAscendis Pharma | $253.29-0.6% | $16.61B | 11 assetsStage unavailable | No dated catalyst |
| AS ASRTAssertio Holdings | $23.50+0.0% | $151.9M | 9 assetsStage unavailable | No dated catalyst |
| AT ATAIATAI Life Sciences | $7.38-0.5% | $2.74B | 13 assetsPhase 2 | VLS-01 (buccal film DMT)Phase 2 · Data readout |
| AT ATHAAthira Pharma | $8.22-4.5% | $26.6M | 5 assetsPhase 3 | Lasofoxifene (Estrogen Modulator)Phase 3 · Data readout |
| AT ATHXAthersys Inc. | $0.00+0.0% | — | 3 assetsStage unavailable | No dated catalyst |
| AT ATNMActinium Pharmaceuticals, Inc. | $1.10-1.8% | $34.5M | 11 assetsStage unavailable | No dated catalyst |
| AT ATOSAtossa Therapeutics | $2.54-1.9% | $25.3M | 7 assetsPhase 2 | (Z)-Endoxifen (Estrogen Modulator)Phase 2 · Data readout |
| AT ATRAAtara Biotherapeutics | $9.70+3.4% | $97.4M | 4 assetsStage unavailable | No dated catalyst |
| AT ATXIAvenue Therapeutics | $0.26+0.0% | $848,783 | 3 assetsStage unavailable | No dated catalyst |
| AT ATXSAstria Therapeutics | $12.58+0.0% | $718.1M | 3 assetsPhase 3 | navenibart (STAR-0215)Phase 3 · Data readout |
| AT ATYRaTyr Pharma, Inc | $0.50-0.3% | $49.2M | 3 assetsPhase 2 | EfzofitimodPhase 2 · Data readout |
| AU AUPHAurinia Pharmaceuticals | $16.65-3.6% | $2.22B | 4 assetsStage unavailable | No dated catalyst |
| AU AURAAura Biosciences Inc | $7.80+0.4% | $808.9M | 5 assetsPhase 3 | Belzupacap Sarotalocan (AU-011) (Virus-Like Conjugate)Phase 2 · Data readout |
| AU AUTLAutolus Therapeutics | $2.41-2.0% | $641.5M | 14 assetsPhase 2 | obe-cel (AUTO1) (CD19) Phase 1 · Data readout |
| AV AVBPArriVent | $29.12-0.2% | $1.44B | 4 assetsPhase 3 | FirmonertinibPhase 3 · Data readout |
| AV AVDLAvadel Pharmaceuticals plc | $21.64+0.0% | $2.12B | 3 assetsStage unavailable | No dated catalyst |
| AV AVEOAVEO Pharmaceuticals / AVEO Oncology | $15.00+0.0% | — | 1 assetsStage unavailable | No dated catalyst |
| AV AVIRAtea Pharmaceuticals | $5.43+1.3% | $435.5M | 5 assetsPhase 3 | Bemnifosbuvir + Ruzasvir (RZR)Phase 3 · Data readout |
| AV AVLNAvalyn Pharma | $38.37+3.3% | $1.70B | 3 assetsPhase 2b | Nintedanib (AP02) (Antifibrotic Therapy)Phase 2 · Data readout |
| AV AVROAvrobio Inc. | — | — | 4 assetsStage unavailable | No dated catalyst |
| AV AVTEAerovate Therapeutics | $21.34+0.5% | $77.7M | 1 assetsStage unavailable | No dated catalyst |
| AV AVTXAvalo Therapeutics | $19.83+0.1% | $1.06B | 10 assetsStage unavailable | No dated catalyst |
| AV AVXLAnavex Life Sciences Corp. | $3.24+3.5% | $300.3M | 6 assetsStage unavailable | No dated catalyst |
| AX AXGNAxogen Inc. | $50.40+8.5% | $2.71B | 1 assetsStage unavailable | No dated catalyst |
| AX AXSMAxsome Therapeutics Inc. | $207.77-0.1% | $10.88B | 16 assetsPDUFA | SolriamfetolPhase 3 · Data readout |
| AY AYLAAyala Pharmaceuticals | $0.50+0.0% | — | 5 assetsStage unavailable | No dated catalyst |
| AZ AZNAstrazeneca | $165.98+0.9% | $257.42B | 98 assetsApproved | No dated catalyst |
| AZ AZTRAzitra | $0.13+4.8% | $8.0M | 4 assetsPhase 1/2 | ATR-04Phase 1/2 · Data readout |
| BB BBIOBridgeBio Pharma Inc | $81.50-1.7% | $15.93B | 13 assetsPDUFA | BBP-418PDUFA · Approval decision |
| BC BCABBioatla Inc | $3.18+0.0% | $5.3M | 6 assetsPhase 1/2 | No dated catalyst |
| BC BCAXBicara Therapeutics | $23.90-2.0% | $1.58B | 3 assetsPhase 2/3 | Ficerafusp alfa -/+ PembrolizumabPhase 1b · Data readout |